薬物排出ステントに関連するリスク

Same author

Re-Evaluating Hepatocellular Carcinoma Diagnosis in Fontan-Associated Liver Disease: Are We Treating the Right Patients at the Right Time?

Journal of gastroenterology and hepatology·2026

Same author

Global gains, metabolic pains: unmasking the hidden burden on liver health.

The lancet. Gastroenterology & hepatology·2026

Same author

Promoting Well-Being Among Gastroenterologists - A Call for Systemic Action.

United European gastroenterology journal·2025

Same author

Reducing alcohol-associated liver disease burden in the general population.

The lancet. Gastroenterology & hepatology·2025

Same author

Estimating inequality in alcohol-related liver disease burden in the UK, 2009 to 2020: a population-based study using routinely collected data.

The Lancet. Primary care·2025

Same author

Association between glucagon-like peptide-1 receptor agonists use and change in alcohol consumption: a systematic review.

EClinicalMedicine·2025

Same journal

Assisted dying and the silencing of medicine's next generation.

Lancet (London, England)·2026

Same journal

Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

Lancet (London, England)·2026

Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026

Same journal

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Lancet (London, England)·2026

Same journal

Research priorities for characterising Bundibugyo virus.

Lancet (London, England)·2026

Same journal

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

Lancet (London, England)·2026

関連する実験動画

薬物排出ステントに関連するリスク

関連する概念動画

Re-Evaluating Hepatocellular Carcinoma Diagnosis in Fontan-Associated Liver Disease: Are We Treating the Right Patients at the Right Time?

Global gains, metabolic pains: unmasking the hidden burden on liver health.

Promoting Well-Being Among Gastroenterologists - A Call for Systemic Action.

Reducing alcohol-associated liver disease burden in the general population.

Estimating inequality in alcohol-related liver disease burden in the UK, 2009 to 2020: a population-based study using routinely collected data.

Association between glucagon-like peptide-1 receptor agonists use and change in alcohol consumption: a systematic review.

Assisted dying and the silencing of medicine's next generation.

Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Research priorities for characterising Bundibugyo virus.

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

関連する実験動画

薬物排出ステントに関連するリスク

関連する概念動画

関連記事

Re-Evaluating Hepatocellular Carcinoma Diagnosis in Fontan-Associated Liver Disease: Are We Treating the Right Patients at the Right Time?

Global gains, metabolic pains: unmasking the hidden burden on liver health.

Promoting Well-Being Among Gastroenterologists - A Call for Systemic Action.

Reducing alcohol-associated liver disease burden in the general population.

Estimating inequality in alcohol-related liver disease burden in the UK, 2009 to 2020: a population-based study using routinely collected data.

Association between glucagon-like peptide-1 receptor agonists use and change in alcohol consumption: a systematic review.

Assisted dying and the silencing of medicine's next generation.

Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Research priorities for characterising Bundibugyo virus.

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.